HCPCS G0483: Drug Test(s), 22 or More Drug Classes, Per Day

Gain a list of the documentation requirements and billing guidelines needed to properly code and use HCPCS code G0483 from our short guide.

Use Code

## **What is HCPCS code G0483?** HCPCS code G0483 represents definitive testing of drugs, using high-complexity methodologies such as GC/MS or LC/MS to qualitatively or quantitatively identify individual drugs, illicit substances, and their metabolites. This code is specifically used when the definitive test covers 22 or more drug classes (including metabolites) and is billed only once per day, inclusive of specimen validity testing. This type of testing (also known as confirmation or quantitative testing) is used as one of the drug identification methods for illicit drugs and their metabolites and typically reports results as concentrations (e.g., ng/mL). It is a more specific and accurate method than presumptive testing. Do note that the code specifies high-complexity methods like Gas Chromatography/Mass Spectrometry (GC/MS) or Liquid Chromatography/Mass Spectrometry (LC/MS), excluding simpler methods like immunoassays. These methods can detect structural isomers and use stable isotopes or other universally recognized internal standards to control for matrix effects and variations in signal strength.

## **G0483 documentation requirements** To ensure proper reimbursement for HCPCS code G0483, healthcare providers must adhere to specific documentation standards: - **Patient history and clinical assessment**: Patient history, physical examination findings, and previous laboratory results. - **Physician's order**: A written order from the treating physician specifying the need for a definitive drug test and listing the 22 or more drug classes to be tested. - **Medical necessity**: Clinical justification for the test, including patient history, symptoms, and any previous test results that necessitate the use of G0483. - **Test results**: Detailed laboratory reports indicating the substances detected, their concentrations, and any metabolites identified. - **Specimen integrity**: Documentation of specimen validity testing to confirm the authenticity and reliability of the sample. - **Current treatment plan**: Documentation of the patient's treatment plan, which may involve Chronic Opioid Therapy (COT) or Substance Use Disorder (SUD) treatment. - **Prescribed medications**: A list of the patient's current prescribed medications. - **Frequency rationale**: The frequency and rationale for the definitive UDT must be individualized and documented, especially if testing exceeds the typical guidelines set by the payor. Maintaining comprehensive records ensures compliance with Medicare and other insurance requirements, facilitating smooth reimbursement processes.

## **G0483 billing requirements** When billing for HCPCS code G0483, providers should adhere to the following guidelines: - **Correct coding**: Ensure that G0483 is the appropriate code for the services rendered, based on the number of drug classes tested. - **Documentation Submission**: Submit all required documentation to support the medical necessity of the test and the services provided. - **Once per day**: Only one definitive drug testing code may be billed per patient, per date of service, regardless of the number of drug classes tested within that code's range. - **Definitive vs. presumptive**: The definitive code (G0483) and a presumptive drug test code (e.g., 80305-80307) generally should not be billed on the same date of service unless a specific payor policy allows it and an appropriate modifier is used (e.g., to indicate separate specimens or medical necessity for both). Check payor-specific Correct Coding Initiative (CCI) edits. - **Specimen validity testing**: Specimen validity testing (SVT) is included in the G0480-G0483 codes and cannot be billed separately. - **Modifier usage**: Payors may require a modifier, such as KX, to indicate that the service was ordered and is medically necessary based on the coverage criteria. - **Frequency limits**: Many payors, including Medicare MACs, impose frequency limitations (e.g., maximum number of units per week, month, or year). Adhering to these billing requirements helps prevent claim denials and ensures timely reimbursement.

## **Other relevant codes** - **G0480**: Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed - **G0481**: Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed - **G0482**: Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed - **G0659**: Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem), excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes

Frequently asked questions

No. Definitive testing is only covered when it is medically necessary to guide patient treatment. Many payors, particularly for commercial and Medicaid plans, have policies that explicitly state that definitive testing for more than 14 drug classes (G0482, G0483) is rarely, if ever, medically necessary and may be non-covered. You must check the specific payor's policy.

Generally, Medicare and most payors allow only one definitive service and one presumptive service per patient per date of service. However, some policies may disallow billing both together on the same day for the same specimen. When allowed, it is typically only when the presumptive test is inconsistent with the clinical picture and the definitive test is necessary to resolve the inconsistency to guide treatment.

Frequency limits are common and vary. For Medicare, the frequency of definitive UDT for patients with 31 to 90 consecutive days of abstinence is often limited, and for G0483, limits may be as restrictive as one unit per 30 days or a low number of total units per year. You must adhere to the specific payor's coverage policy.